A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer

Cuneo, Kyle C.; Chenevert, Thomas L.; Feng, Mary; Ben‐Josef, Edgar; Feng, Felix Y.; Greenson, Joel K.; Schipper, Matthew J.; Lawrence, Theodore S.; Ross, Brian D.

doi:10.1016/j.ijrobp.2014.05.1150

Cited by 13 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the feasibility of an early response assessment by DWI has been investigated in various studies; they showed that ADC helped predicting solid tumour response before significant changes in lesiondiameter occurred [10,11,13,[26][27][28]. More recently, it was shown that DWI provided diagnostic information similar to positron emission tomography/computed tomography (PET/ CT) in assessing early response to radioembolization.…”

Section: Discussionmentioning

confidence: 99%

Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy

et al. 2016

View full text Add to dashboard Cite

• Relative minADC changes may predict survival in liver-predominant metastatic colorectal cancer following SIRT • Intratumoral minADC changes by ≥22 % were best to predict an improved overall survival • Functional imaging response assessment is feasible before anatomic tumour-size changes occur • minADC changes might guide future therapy management in sequential lobar radioembolization approaches.

show abstract

Section: Discussionmentioning

confidence: 99%

Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Patients underwent MRI within 3 weeks preceding neoadjuvant therapy and 5 weeks after the last dose. The setting of MRI scans and the diffusion‐weighted technique were similar to those of a previous study except for the b ‐values (0, 50, 800 s/mm 2 ). The same MRI (MRI system/scanner, Intera Achieva 1.5T from Philips Medical Systems, Best, The Netherlands) in the independent institution outside of the hospital was used for all patients analyzed in this study.…”

Section: Methodsmentioning

confidence: 99%

“…Cuneo et al. reported that DW‐MRI may be useful to predict histological response to neoadjuvant therapy in resectable pancreatic cancer in their pilot study . However, there has been no study that investigated its usefulness in the prediction of histological response to neoadjuvant therapy in patients with BRPC.…”

Section: Introductionmentioning

confidence: 99%

Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma

Okada

Hirono

Kawai

et al. 2017

J Hepatobiliary Pancreat Sci

View full text Add to dashboard Cite

show abstract

“…Tumor progression rate was significantly higher in patients with low ADC values than in those with higher values. Cuneo et al [134] reported a significant correlation Regarding PanNETs, Yao et al [135] reported that bevacizumab was associated with a 44% decrease in BF in patients with low-to intermediate grade tumors; the addition of everolimus induced a further 29% BF decrease. Everolimus alone was associated with 13% increase in MTT.…”

Section: Pancreatic Tumorsmentioning

confidence: 99%

“…De Bruyne et al [127] 19 DCE-MRI AUC decrease CRC metastases Bevacizumab Vriens et al [129] 23 DCE-MRI K trans decrease CRC metastases Cytotoxic therapy Coenegrachts et al [130] 10 DCE-MRI Kep increase CRC metastases Bevacizumab + FOLFIRI Deckers et al [126] 20 DWI ADC decrease CRC metastases Chemotherapy Niwa et al [133] 63 DWI ADC decrease PDAC Gemcitabine Cuneo et al [134] 12 DWI ADC increase PDAC Chemoradiation Yao et al [135] 39 pCT BF decrease PanNET Bevacizumab ± everolimus Miyazaki et al [132] [115,116] .…”

Section: Primary Liver Tumorsmentioning

confidence: 99%

Prognostication and response assessment in liver and pancreatic tumors: The new imaging

Robertis¹,

Martini²,

Demozzi³

et al. 2015

WJG

View full text Add to dashboard Cite

Diffusion-weighted imaging (DWI), dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) and perfusion computed tomography (CT) are technical improvements of morphologic imaging that can evaluate functional properties of hepato-bilio-pancreatic tumors during conventional MRI or CT examinations. Nevertheless, the term "functional imaging" is commonly used to describe molecular imaging techniques, as positron emission tomography (PET) CT/MRI, which still represent the most widely used methods for the evaluation of functional properties of solid neoplasms; unlike PET or single photon emission computed tomography, functional imaging techniques applied to conventional MRI/CT examinations do not require the administration of radiolabeled drugs or specific equipments. Moreover, DWI and DCE-MRI can be performed during the same session, thus providing a comprehensive "one-step" morphological and functional evaluation of hepato-bilio-pancreatic tumors. Literature data reveal that functional imaging techniques could be proposed for the evaluation of these tumors before treatment, given that they may improve staging and predict prognosis or clinical outcome. Microscopic changes within neoplastic tissues induced by treatments can be detected and quantified with functional imaging, therefore these techniques could be used also for posttreatment assessment, even at an early stage. or altered cellular membranes will present diffusion restriction, which is depicted as signal hyperintensity areas on high b-value DW images and hypointensity on the apparent diffusion coefficient (ADC) maps; ADC measurement can also quantify water molecules' diffusion. As dedifferentiation or therapies may induce microscopic changes in neoplastic tissues that could modify water molecules' diffusion, DWI can distinguish between different degrees of malignancy and can be also proposed for post-treatment monitoring. Moreover, DWI can be performed in a single session with DCE-MRI, thus providing a comprehensive "one-step" morphological and functional evaluation of hepatobilio-pancreatic tumors.Perfusion imaging techniques evaluate changes in signal intensity (DCE-MRI) or density (pCT) after contrast medium injection, being therefore able to assess microvascularization through the evaluation of the dynamics of contrast medium distribution from vessels to the neoplastic tissue. Perfusion parameters are therefore theoretically good candidates for the evaluation of microscopic vascular differences between lesions with different pathological grade and for the assessment of treatment response, especially after chemoembolization or during treatments with antiangiogenic drugs.This editorial analyzes up-to-date literature data regarding the application of functional imaging techniques, apart from molecular imaging, to hepatic and pancreatic tumors, with particular emphasis on correlations to pathological features, prognostic stratification and therapeutic response assessment. FUNCTIONAL IMAGING TECHNIQUES: TECHNICAL BASESIn 1965 Stejskal and Tanne...

show abstract

A Pilot Study of Diffusion-Weighted MRI in Patients Undergoing Neoadjuvant Chemoradiation for Pancreatic Cancer

Cited by 13 publications

References 15 publications

Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy

Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy

Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma

Prognostication and response assessment in liver and pancreatic tumors: The new imaging

Contact Info

Product

Resources

About